1. Aratana Therapeutics Adds David Brinkley to Board of Directors

    Aratana Therapeutics Adds David Brinkley to Board of Directors

    KANSAS CITY, Kan., March 27, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors.  Mr. Brinkley's broad expertise spans business development, marketing, and animal health, for both mid- and large size biopharmaceutical companies.

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Topics Mentioned